Cargando…
Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemia
BACKGROUND: Chronic lymphocytic leukaemia (CLL) patients display a highly variable clinical course, with progressive acquisition of drug resistance. We sought to identify aberrant epigenetic traits that are enriched following exposure to treatment that could impact patient response to therapy. METHO...
Autores principales: | Barrow, Timothy M., Nakjang, Sirintra, Lafta, Fadhel, Bilotkach, Kateryna, Woodhouse, Laura, Junge, Gesa, Tudhope, Susan J., Wallis, Jonathan P., Marr, Helen, Marshall, Scott, Bown, Nick, Willmore, Elaine, Strathdee, Gordon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852668/ https://www.ncbi.nlm.nih.gov/pubmed/33082556 http://dx.doi.org/10.1038/s41416-020-01117-8 |
Ejemplares similares
-
PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia
por: Herriott, Ashleigh, et al.
Publicado: (2015) -
SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia
por: Aptullahoglu, Erhan, et al.
Publicado: (2023) -
Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells
por: Ciardullo, Carmela, et al.
Publicado: (2019) -
Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition
por: Aptullahoglu, Erhan, et al.
Publicado: (2023) -
Expression and Activity of the NF-κB Subunits in Chronic Lymphocytic Leukaemia: A Role for RelB and Non-Canonical Signalling
por: Mulligan, Evan A., et al.
Publicado: (2023)